SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Clinical trial NCT05307328 · COMPLETED

Trial details

NCT number: NCT05307328
Sponsor: Sparrow Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Cushing's Syndrome I Cushing Disease Due to Increased ACTH Secretion Cortisol Excess Cortisol; Hypersecretion Cortisol Overproduction Ectopic ACTH Secretion

Start date: 2022-09-01
Primary completion: 2025-08-01
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.